Life Sciences & Healthcare

Navigating innovation, regulation and risk in the Life Sciences and Healthcare industry

Overview

The life sciences and healthcare sector is evolving rapidly. Advances in biotechnology, medical devices, digital health, artificial intelligence and precision medicine are creating new opportunities for organisations across the health industry, while regulatory scrutiny, product liability exposure and commercial complexity are increasing.

With more than 30 years' experience advising organisations operating in highly regulated environments, Clayton Utz life sciences and healthcare lawyers support clients across the full life sciences and healthcare landscape, including pharmaceutical and biotechnology companies, medical device and diagnostics manufacturers, digital health providers, healthcare organisations, industry bodies and government agencies.

Our multidisciplinary team understands the unique challenges associated with developing, commercialising and defending innovative products and technologies. We advise clients throughout the product lifecycle - from research and development, clinical trials and market entry, through to regulatory compliance, commercialisation, investigations, disputes and product liability claims.

Combining deep sector knowledge with expertise across regulatory compliance, intellectual property, commercial transactions, competition, technology, investigations, class actions and product liability, we help clients navigate complexity, manage risk and achieve their commercial objectives.

Recognition

  • Band 1, Life Sciences Chambers Asia Pacific

  • Band 1, Government – Chambers Asia Pacific

Clayton Utz has understanding of the issues as related to combination therapies and their place in modern treatment algorithms.

– Chambers Asia Pacific, Life Sciences

Explore how our team supports clients across the life sciences and healthcare sector


Navigating Australia's complex regulatory framework requires more than technical legal advice. Our team regularly advises on therapeutic goods regulation and helps organisations manage compliance obligations (specifically with the TGA, PBS, and Medicines Australia Code), engage with regulators, bring products to market and respond to regulatory scrutiny.


Innovation is the foundation of the life sciences sector, and intellectual property plays a critical role in driving and protecting commercial success. We assist clients to protect, commercialise and enforce their patent and intellectual property rights, helping maximise the value of innovation and research.


Product safety issues can have significant commercial and reputational consequences. We advise clients on risk management, product recalls, investigations and complex pharmaceutical product liability litigation, as well as medical negligence litigation matters.


Life sciences companies increasingly face collective claims arising from product safety concerns, consumer protection issues and regulatory developments. Our team has extensive experience defending complex class action proceedings.


We advise healthcare providers, hospitals, aged care operators, government agencies and other healthcare stakeholders on the legal, regulatory and operational challenges associated with delivering healthcare services in a rapidly changing environment.


We advise pharmaceutical, biotechnology, medical device and healthcare businesses on mergers and acquisitions, capital raising, joint ventures, corporate governance and strategic investments.

Our team to support you

Toolkits

Insights
Fifty years of foreign investment regulation in Australia: The Foreign Acquisitions and Takeovers Act 1975, and what may come
28 Jul 2026 | Article
Read Insights
A new industrial court for Australia: what we know about the proposed Fair Work Court and its impact on employers
24 Jul 2026 | Article
Read Insights
Healthcare software: TGA clarifies when AI will be regulated as a medical device
24 Jul 2026 | Article
Read Insights
Legislating the Australian trade playbook: What the Trade and Investment Agreements (Consultation) Bill means for your business
16 Jul 2026 | Article
Read Insights
The Australia–India Annual Summit: from ECTA to CECA, and what it means for business
16 Jul 2026 | Article
Read Insights
Australia's Enhanced CIRMP Rules: what critical infrastructure operators need to know
23 Jun 2026 | Article
Read Insights
ASIC v Bekier: Ten D&O insurance and indemnity considerations
19 Jun 2026 | Article
Read Insights
ASIC v Bekier: Federal Court imposes $1.1 million in penalties and lengthy disqualification, and costs against former Star Entertainment CEO and General Counsel
17 Jun 2026 | Article
Read Insights
ASIC v Bekier: ASIC seeks millions in penalties and lengthy disqualification of former officers of Star Entertainment
3 Jun 2026 | Article
Read Insights
Annual Wage Review 2026: the immediate compliance impacts –and beyond
3 Jun 2026 | Article
Read Insights
Address psychosocial hazards in workplace investigations to protect your people and organisation
28 May 2026 | Article
Read Insights
Incoming changes to Australia's foreign investment framework: What investors need to know
20 May 2026 | Article
Read Insights